NCT06453668CompletedPhase 1
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)
Source: EU CTIS (euclinicaltrials.eu) · Last updated 11 Jun 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 107 (actual)
- First submitted
- 14 Sept 2023
- Start date
- 6 Nov 2025
- Lead sponsor
- Itb-Med AB
- Diseases
- ALS (motor neurone disease)
- NCT number
- NCT06453668
- EU CT number
- 2023-506174-12-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 107
- 6 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Charite Universitaetsmedizin Berlin KöR Coordinator of this site? Confirm its status | Berlin | Germany | Completed |
| Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. Coordinator of this site? Confirm its status | Bonn | Germany | Completed |
| Universitaetsklinikum Ulm AoR Coordinator of this site? Confirm its status | Ulm | Germany | Completed |
| University Of Skane Coordinator of this site? Confirm its status | Malmo | Sweden | Completed |
| Region Stockholm – SLSO Coordinator of this site? Confirm its status | Stockholm | Sweden | Completed |
| Norrlands University Hospital Coordinator of this site? Confirm its status | Umeå | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.